<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323178</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-LMMC-Eltrombopag</org_study_id>
    <secondary_id>2013-001779-19</secondary_id>
    <nct_id>NCT02323178</nct_id>
  </id_info>
  <brief_title>A Study of Eltrombopag in Patients With CMML and Thrombocytopenia</brief_title>
  <official_title>A Phase I/II Study of Eltrombopag in Patients With Chronic Myelomonocytic Leukemia and Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of patients with chronic myelomonocytic leukemia (CMML) and thrombocytopenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All eligible patients will be treated with eltrombopag for a minimum of twelve weeks and a
      maximum of 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet response</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hematological improvement after twelve weeks of eltrombopag treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of platelet response</measure>
    <time_frame>30 months</time_frame>
    <description>Duration of platelet response at end of follow-up</description>
  </secondary_outcome>
  <other_outcome>
    <measure>safety of eltrombopag assessed by clinical and biological toxicity of eltrombopag evaluated using NCI CTCAE v4.0</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>CMML</condition>
  <condition>Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>eltrombopag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eltrombopag</intervention_name>
    <description>initial dose of 50 mg once daily, then the dose can be sequentially increased every 2 weeks up to a maximum dose of 300mg/day</description>
    <arm_group_label>eltrombopag</arm_group_label>
    <other_name>revolade</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Chronic myelomonocytic leukemia (CMML) according to WHO criteria:

          -  Stable excess in blood monocytes &gt; 1 G/L

          -  Lack of bcr-abl rearrangement (or Philadelphia chromosome)

          -  Bone marrow blast cells &lt; 20%

          -  Dysplasia of at least one lineage or clonality marker or blood monocytosis during more
             than 3 months w/o other explanation

          -  Platelet counts &lt; 50 G/L on two successive blood counts in the 2 weeks preceding
             inclusion

          -  Either of D1 or D2 criteria:

          -  Lack of features of advanced disease If white blood cell count (WBC) &lt; 13 G/L:
             International Prognostic Scoring System (IPSS) low or intermediate-1

        If WBC ≥ 13 G/L: no more than one of the following criteria:

          -  Clonal cytogenetic abnormality other than t(5;12) (q33; p13)

          -  Absolute neutrophil count (ANC) &gt; 16 G/L

          -  Anemia (Hb &lt; 100 g/L)

          -  Extramedullary localization (documented cutaneous, pleural or pericardial effusion,
             etc…) OR D2- Features of advanced disease If WBC &lt; 13 G/L: IPSS intermediate-2 or high

        If WBC ≥ 13 G/L: two or more of the following criteria:

          -  Clonal cytogenetic abnormality other than t(5;12) (q33; p13)

          -  ANC &gt; 16 G/L

          -  Anemia (Hb &lt; 100 g/L)

          -  Extramedullary localization (documented cutaneous, pleural or pericardial effusion,
             etc…) And having resisted (progression or stable disease without hematological
             improvement according to International Working Group (IWG) 2006 criteria) or relapsed
             after a treatment with a hypomethylating agent (azacitidine or decitabine for a
             minimum of 6 cycles)

          -  Blast cells ≤ 5% in the bone marrow

          -  Performance status 0-2 on the Eastern Cooperative Oncology Group (ECOG) Scale

          -  Serum Creatinin &lt; 2 times the upper limit of normal (ULN)

          -  Alanine transaminase (ALT) and aspartate transaminase (AST) &lt; 3 ULN, total bilirubin &lt;
             1.5 ULN (except Gilbert Syndrome)

          -  Adequate contraception if relevant

          -  Signed informed consent

        Exclusion Criteria:

          -  CMML with t(5 ;12) or Platelet-derived growth factor beta receptor (PDGFbetaR)
             rearrangement

          -  Acute blastic transformation of CMML with bone marrow blast cells &gt; 20%

          -  Bone marrow blast cells &gt; 5%

          -  Patients eligible for allogeneic bone marrow transplantation with an identified donor

          -  Intensive chemotherapy given less than 3 months before inclusion

          -  Pregnant or breastfeeding

          -  Hepatitis C infection

          -  Splenomegaly &gt; 16 cm by ultrasound or CT scan (Not Applicable in patients without
             palpable splenomegaly)

          -  Significant (grade II-IV) myelofibrosis (bone marrow trephine if bone marrow aspirate
             with poor cellularity, or features of myelofibrosis on the peripheral blood smear
             (teardrop erythrocytes)

          -  Clinically relevant thromboembolic risk factor which, in the investigator's opinion,
             is such that the benefit/risk ratio becomes unfavourable if platelet counts increase

          -  Liver cirrhosis (Child-Pugh score ≥ 5)

          -  Prior Cancer (except in situ cervix carcinoma, limited basal cell carcinoma, or other
             tumors if not active during the last 3 years)

          -  Serious concomitant systemic disorder, including active bacterial, fungal or viral
             infection that, in the opinion of the investigator, would compromise the safety of the
             patient and/or his/her ability to complete the study.

          -  Hypersensitivity to Eltrombopag
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphaël Itzykson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint-Louis Hospital, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Fenaux, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Saint-Louis Hospital, Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raphaël Itzykson, MD</last_name>
    <phone>+33 1 42 38 51 27</phone>
    <email>raphael.itzykson@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre Fenaux, MD, PHD</last_name>
    <phone>+33 1 71 20 70 18</phone>
    <email>pierre.fenaux@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bérengère Gruson, MD</last_name>
      <phone>+33 3 22 45 59 85</phone>
      <email>gruson.berengere@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Bérengère Gruson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49 033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde Hunault, MD, PHD</last_name>
      <phone>+33 2 41 35 44 75</phone>
      <email>MaHunault@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Mathilde Hunault, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmad Al Jijakli, MD</last_name>
      <phone>+33 1 34 23 22 39</phone>
      <email>ahmad.aljijakli@ch-argenteuil.fr</email>
    </contact>
    <investigator>
      <last_name>Ahmad Al Jijakli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Braun, MD</last_name>
      <phone>+33 1 48 95 70 57</phone>
      <email>thorsten.braun@avc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Thorsten Braun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital privé Sévigné</name>
      <address>
        <city>Cesson-Sévigné</city>
        <zip>35510</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benoit BAREAU, MD</last_name>
      <phone>+33 2 23 21 05 50</phone>
      <email>benoit.bareau@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Benoit Bareau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Toma, MD</last_name>
      <phone>+33 1 49 81 20 57</phone>
      <email>andrea.toma@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Andréa Toma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Park, MD, PHD</last_name>
      <phone>+33 4 76 76 62 77</phone>
      <email>spark@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Park, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamel Laribi, MD</last_name>
      <phone>+33 2 43 43 43 61</phone>
      <email>klaribi@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Kamel Laribi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Pierre Gourin, MD</last_name>
      <phone>+33 5 55 05 66 42</phone>
      <email>marie-pierre.gourin@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Pierre Gourin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Wattel, MD, PHD</last_name>
      <phone>+33 4 72 11 74 01</phone>
      <email>wattel@lyon.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Wattel, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Vey, MD, PHD</last_name>
      <phone>+33 4 91 22 36 67</phone>
      <email>veyn@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Norbert Vey, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc Fouillard, MD</last_name>
      <phone>+33 1 64 65 38 76</phone>
      <email>l-fouillard@ch-meaux.fr</email>
    </contact>
    <investigator>
      <last_name>Loïc Fouillard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Peterlin, MD</last_name>
      <phone>+33 2 40 08 32 71</phone>
      <email>pierre.peterlin@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Peterlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Delaunay, MD</last_name>
      <phone>+33 2 28 25 52 54</phone>
      <email>delaunay.jacques@catherinedesienne.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Delaunay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Legros, MD</last_name>
      <phone>+ 33 4 92 03 58 44</phone>
      <email>legros.l@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence Legros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis - Service d'hématologie AJA</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raphaël Itzykson, MD</last_name>
      <phone>+33 1 42 38 51 27</phone>
      <email>raphael.itzykson@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Raphaël Itzykson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis - Service d'hématologie séniors</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Fenaux, MD, PHD</last_name>
      <phone>+33 1 70 20 70 22</phone>
      <email>pierre.fenaux@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Fenaux, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Haut-Lévèque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Dimicoli-Salazar, MD</last_name>
      <phone>+33 5 57 65 65 11</phone>
      <email>sophie.dimicoli-salazar@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie Dimicoli-Salazar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Miguel Torregrosa Diaz, MD</last_name>
      <phone>+33 5 48 44 44 44</phone>
      <email>jose-miguel.torregrosa-diaz@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Jose Miguel Torregrosa Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la région d'Annecy</name>
      <address>
        <city>Pringy cedex</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascale Cony-Makhoul, MD</last_name>
      <phone>+33 4 50 63 66 08</phone>
      <email>pconymakhoul@ch-annecy.fr</email>
    </contact>
    <investigator>
      <last_name>Pascale Cony-Makhoul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stanislas Nimubona, MD</last_name>
      <phone>+33 2 99 28 95 21</phone>
      <email>stanislas.nimubona@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Stanislas Nimubona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aspasia Stamatoullas, MD</last_name>
      <phone>+33 2 32 08 22 88</phone>
      <email>aspasia.stamatoullas@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Aspasia Stamatoullas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan - Médecine interne</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Odile Beyne-Rauzy, MD, PHD</last_name>
      <phone>+33 5 61 77 96 95</phone>
      <email>beynerauzy.o@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Odile Beyne-Rauzy, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan - Service d'Hématologie Clinique</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Recher, MD</last_name>
      <phone>+ 33 5 61 77 20 78</phone>
      <email>recher.c@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Christian Recher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnès Guerci-Bresler, MD</last_name>
      <phone>+33 3 83 15 32 81</phone>
      <email>a.guerci@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Agnès Guerci-Bresler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Solary, MD, PHD</last_name>
      <phone>+33 1 42 11 42 11</phone>
      <email>eric.solary@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Solary, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic myelomonocytic leukemia</keyword>
  <keyword>thrombocytopenia</keyword>
  <keyword>eltrombopag</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

